Significant progress has been made in the development of a new vaccine against Staphylococcus aureus infections.

Intervacc is now proceeding in the development of a vaccine against infections caused by Staphylococcus aureus. A method has been developed that significantly simplifies and streamlines the production of components included in a new vaccine, INV412, against S. aureus infections. The vaccine candidate INV412 consists of several fused proteins and has been developed using the new method. Several of the components included in previous studies have resulted in protective antibodies. The concept behind INV412 is a development of the strategy used for Strangvac®, Intervacc's vaccine against strangles in the horse.

"This is very exciting and an additional important step in Intervacc's development to become a company with several projects with high-potential in addition to Strangvac® and INV274 against pig streptococcal infection," says Jan-Ingmar Flock, CEO Intervacc AB in a comment.

Mastitis (udder infection) on cows is a global problem and is often caused by S. aureus, and the primary target group for Intervacc will be cows when the effect of INV412 has been documented. The costs related to mastitis are estimated annually to amount to approximately 200 MSEK only in Sweden and in the US approximately 4500 MSEK. The need for a vaccine to complement other preventive measures is very large.

Because S. aureus can cause severe infections, which are often difficult to treat in humans, experiences gained from INV412 on cow may be taken further for future development of a vaccine against human infections with S. aureus. Vaccination against bacterial infections is seen as one of the most important measures to reduce overuse of antibiotics, which has led to devastating problems with resistance development and spread of MRSA (Methicillin Resistant S. aureus).

For more information please contact:

Jan-Ingmar Flock, CEO

E-mail: jan-ingmar.flock@intervacc.com

Phone: +46-8-120 10 602 or +46-73-334 14 11

This information is information that Intervacc AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on January 10, 2018.

About Intervacc

Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the NASDAQ First North market since April 2017 with Remium Nordic Holding AB as Certified Adviser.

Tags:

About Us

Intervacc develop novel veterinary vaccines and the pipeline is based on new technology using recombinant proteins rather than attenuated live strains found in conventional vaccines. This results in vaccines with much lower incidence of side effects usually seen with conventional vaccines, something we take pride in as it greatly contributes to an improved animal welfare.

Subscribe

Quotes

This is very exciting and an additional important step in Intervacc's development to become a company with several projects with high-potential in addition to Strangvac® and INV274 against pig streptococcal infection
Jan-Ingmar Flock, CEO